Close Menu
    Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Public Health

    Blood Types and Coronavirus: Are People With Blood Group A Really at Higher Risk?

    By Sakthivel Vaiyapuri, University of ReadingMarch 24, 2020
    Credit: angellodeco / Shutterstock
    Share
    Facebook LinkedIn Reddit Email

    A recent study from China, which has not been peer reviewed yet, suggests a link between having blood group A and a higher risk of getting COVID-19, compared with people who have blood group O. But is this really the case?

    As many of us know, there are different blood groups found in humans. Primarily, we differentiate between the A, B, AB and O blood groups. These mean a distinctive sugar molecule is present on the surface of red blood cells for each group.

    Commonly, more people are blood group O than blood group A and other groups. For example, in the UK, 48% of people possess blood group O while 38%, 10% and 3% have A, B and AB blood groups, respectively.

    The differentiation by blood grouping plays a critical role during blood donation and transfusion to patients. Although the blood-grouping molecules play a role in red blood cells, we do not fully understand their function.

    Differentiating blood groups is critical for blood donations. LightField Studios/Shutterstock

    The recent Chinese study, conducted by researchers including from the Zhongnan Hospital at Wuhan University, retrospectively analysed the blood groups of patients from three hospitals in China, two in Wuhan and one in Shenzhen. All of the 2,173 patients had been diagnosed with COVID-19.

    At the Wuhan Jinyintan Hospital, they also analysed blood types of 3,694 people who didn’t have COVID-19 and found that 32% had blood group A and 34% had blood group O. Among the 1,775 COVID-19 patients at the hospital, 38% had blood group A and 26% blood group O.

    For the other Wuhan hospital in the study – Renmin Hospital of Wuhan University – they did not provide data for the control population. But of the 113 COVID-19 patients they analysed, 40% had blood group A and 25% blood group O.

    At Shenzhen Third People’s Hospital, 29% of the control population (23,386) had blood group A and 39% blood group O. And of the 285 COVID-19 patients, 28.8% had blood group A and 28.4% blood group O. Although there was a significant difference between the patients of COVID-19 with blood groups A and O in the Wuhan hospitals, there was no significant difference in the Shenzhen hospital.

    No firm conclusion

    To date, we don’t have robust scientific evidence to prove that our blood group has a direct relationship with COVID-19 infection. In this observational study, if they considered several other parameters, such as the previous history of other – specifically immune or respiratory-related – diseases, the conclusions might have been different. They have also not explained why they failed to see a significant difference between the blood groups in the Shenzhen hospital. And given COVID-19 is a pandemic, the sample size that they have analysed is not sufficient to draw firm conclusions.

    We now need more detailed scientific research to establish the relationship between blood groups and COVID-19 and possibly other viral infections. In the meantime, people should continue to follow the advice provided by their healthcare professionals, government authorities and the WHO to avoid this infection and to control its spread, regardless of which blood group they have.

    ABOUT THE AUTHOR

    Sakthivel Vaiyapuri, Associate Professor in Cardiovascular & Venom Pharmacology, University of Reading

    This article is republished from The Conversation under a Creative Commons license. Read the original article.

    Coronavirus COVID-19 Editor Pick Magazine Edition 11 April 2020 SARS-CoV-2
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleFDA Allows Emergency Use of Investigational Convalescent Plasma for Critical COVID-19 Patients
    Next Article WUSTL Researchers Investigate Transfusion of Antibodies from Recovered Patients’ as COVID-19 Treatment

    Related Stories

    First Light Diagnostics Receives FDA Clearance for Rapid Anthrax Test

    December 5, 2023

    Chlorine Exposure Biomarkers in a Large Animal Model

    December 5, 2023

    ARPA-H Announces New Tiered Proposal Submission System to Reduce Applicant Barriers

    December 5, 2023

    Needle-Free Vaccine Patch Against Zika Virus

    December 2, 2023
    News Scan

    Biodefense Headlines – 30 November 2023

    News Scan November 30, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include the largest ever outbreak of mpox in the DRC; launch of National Wastewater Surveillance Program dashboard; low uptake of COVID-19 boosters and flu vaccines;…

    Upcoming Events

    Dec 6
    Virtual Event Virtual Event
    6:00 am - 7:00 am EST

    AMR One Health Priority Research Agenda: Transmission

    Mar 12
    Virtual Event Hybrid Event
    March 12, 2024 - March 17, 2024

    2024 Fungal Genetics Conference

    Mar 21
    March 21, 2024 - March 23, 2024

    ASPPH 2024 Annual Meeting

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    News on pathogens and preparedness for public health emergencies

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.